ClinicalTrials.gg
Not yet recruitingNCT06006104Updated Aug 23, 2023

Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer

A Phase 1/2 interventional study of HRS-4357 injection in Advanced Prostate Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Not yet recruiting. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-23.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 1 month ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd. — 14 open to participants now, 17 under way, 4 of them phase 3. Prostatic Neoplasms · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
20th of 31
49 · median 69
Started
2023
with 3 others
Phase 1/2
7 of 31
5 open now
Primary completion
2024-09
later than 2 of 16 live
Registered
17th of 31
by date

Among the 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 20th largest by planned enrollment, is one of 4 that started in 2023, is one of 7 in phase 1/2, reaches primary completion later than 2 of the 16 other live ones, and was the 17th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

14 of the 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

The study is being conducted to evaluate the the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of HRS-4357 injection in adult patients with advanced prostate cancer.

03

Conditions studied

  • Advanced Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation in this clinical trial, understanding of the study procedures and being able to sign the form in writing;
  2. Male, age ≥18 years;
  3. score 0 - 1;
  4. and/or cytologically confirmed adenocarcinoma of the prostate;

Exclusion criteria

Exclusion Criteria:

  1. Spinal cord compression with clinical symptoms, or clinical symptoms and/or imaging findings suggesting imminent spinal cord compression.
  2. Severe urinary incontinence, hydronephrosis, severe micturition dysfunction, etc. Note: Subjects with bladder outflow obstruction or urinary incontinence that can be controlled by the best available standard of care (including pads, drainage, etc.) are eligible to participate in the study.
  3. Active syphilis infection.
  4. Known to components of the study drug or its analogues.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (estimated)

Study arms

  • Experimental
    HRS-4357 injection

    Drug: HRS-4357 injection

Interventions

  • DrugHRS-4357 injection

    HRS-4357 injection

06

What researchers measure

Primary outcomes

  1. Prog Dose limiting toxicity (DLT)

    Time frame: up to 9 months follow-up

  2. recommended phase 2 dose (RP2D)

    Time frame: up to 9 months follow-up

  3. recommended dosing cycle.

    Time frame: up to 9 months follow-up

  4. PSA50 response rate

    Time frame: up to 12 weeks follow-up

Secondary outcomes

  1. Maximum plasma concentration (Cmax)

    Time frame: up to 6 weeks follow-up

  2. time to maximum plasma concentration (Tmax)

    Time frame: up to 6 weeks follow-up

  3. area under the plasma concentration-time curve (AUC)

    Time frame: up to 6 weeks follow-up

  4. clearance (Cl)

    Time frame: up to 6 weeks follow-up

  5. volume of distribution (Vz)

    Time frame: up to 6 weeks follow-up

  6. terminal half-life (t1/2)

    Time frame: up to 6 weeks follow-up

  7. cumulative urinary excretion of radioactive dose

    Time frame: up to 6 weeks follow-up

  8. Absorbed dose and effective dose of radioactive internal irradiation of the whole body and major organs;

    Time frame: up to 6 weeks follow-up

  9. PSA90 response rate

    Time frame: up to 12 weeks follow-up]

  10. time to PSA progression

    Time frame: up to 9 months follow-up

  11. Overall Response Rate (ORR)

    Time frame: up to 20 months follow-up

  12. Disease control Rate (DCR)

    Time frame: up to 20 months follow-up

  13. Duration of Response (DoR)

    Time frame: up to 20 months follow-up

  14. Radiographic Progression-free Survival (rPFS)

    Time frame: up to 9 months follow-up

  15. Overall Survival (OS)

    Time frame: up to 20 months follow-up

  16. Incidence and severity of AEs and SAEs

    Time frame: up to 20 months follow-up

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2023; primary completion for Sep 2024, 12 months later.

Of 97 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 12 months is below that.

Counting every sponsor, half of 211 studies reached it within 61 months; a quarter within 30 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2023
First posted
Aug 23, 2023
StartEst.
Sep 30, 2023
Primary completionEst.
Sep 30, 2024
CompletionEst.
Oct 31, 2024
Last update
Aug 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06006104
Responsible party
Sponsor
First posted
Aug 23, 2023
Start date
Sep 30, 2023 (estimated)
Primary completion
Sep 30, 2024 (estimated)
Completion
Oct 31, 2024 (estimated)
Last update
Aug 23, 2023

Study contacts

Xueying Zheng
Contact
xueying.zheng.xz17@hengrui.com
+0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion